Financial impact of two different ways of evaluating early virological response to peginterferon-α-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1

PharmacoEconomics

Volumn 23, Issue 10, 2005, Pages 1043-1055

  Buti, Maria ^a   Casado, Miguel A ^b   Fosbrook, Leslie ^c   Esteban, Rafael ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

^c Schering Plough   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIGEN; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA;

ADULT; AGED; ARTICLE; DECISION MAKING; EVALUATION; GENOTYPE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; PARAMETER; PATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SPAIN; VIROLOGY; VIRUS DETECTION; VIRUS INFECTION;

ANTIVIRAL AGENTS; DECISION TREES; DRUG THERAPY, COMBINATION; ECONOMICS, PHARMACEUTICAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MULTICENTER STUDIES; RIBAVIRIN; SENSITIVITY AND SPECIFICITY; SPAIN;

EID: 27744443815     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523100-00007     Document Type: Article

References (34)

1. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C 2002 Jun 10-12. Gastroenterology 2002; 123: 2082-99
2. EASL International Consensus Conference on Hepatitis C. Paris, 1999 Feb 26-28. J Hepatol 1999; 30: 956-61
3. Alberti A, Noventa F, Benvegnú L, et al. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-4
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65
5. Fried MW, Shiffman ML, Reddy RK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82
6. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55
7. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 1554-68
8. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-9
9. Zeuzem S, Lee J-H, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-56
10. Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002; 37: 500-6
11. Detmer J, Lagier R, Flynn J, et al. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 1996; 34: 901-7
12. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52
13. Wong JB, Davis G, McHutchison JG, et al. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98: 2354-62
14. Tanaka E, Kiyosawa K, Matsumoto A, et al. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1996; 23: 1330-3
15. Bouvier-Alias M, Patel K, Dahari H, et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002; 36: 211-8
16. Buti M, San Miguel R, Brosa M, et al. Estimating the impact of HCV therapy on the future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42: 639-45
17. Gagni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics 2003; 21: 149-57
18. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21: 89-103
19. Darba J. Pharmaceutical expenditure and therapeutic value of new medicines in Spain. Pharmacoeconomics 2003; 21: 1211-2
20. Chambers M, Hutton J, Nuitjen M. Budget impact analysis for health technology appraisal: development and application within the NICE appraisal process. J Clin Excellence 2002; 4: 203-6
21. Pradat P, Maynard M, Buti M, et al. The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment. J Med Virol 2004; 73: 392-6
22. Rebucci C, Cerino A, Cividine A, et al. Monitoring response to antiviral for patients with chronic hepatitis C virus infection by core-antigen assay. J Clin Microbiol 2003; 41: 3881-4
23. Buti M, Mendez C, Schaper M, et al. Hepatitis C virus core antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alfa 2b plus ribavirin. J Hepatol 2004; 40: 527-32
24. General Spanish Council of Pharmacists. Catalogue of Medicinal Products, 2003.
25. Buti M, Medina M, Casado MA, et al. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 687-94
26. National Statistics Institute. Consumer Price Index [online]. Available from URL: http://www.ine.es [Accessed 2005 Sep 5]
27. Drummond MF, O'Brien B, Stoddart GL, et al. Basic types of economic evaluation. Critical assessment of economic evaluation. In: Drummond MF, O'Brien B, Stoddart GL, et al., editors. Methods for the economic evaluation of health care programmers. 2nd ed. Oxford: Oxford University Press, 1997
28. Beilby JJ, Pekarsky B. Fundholding: learning from the past and looking for the future. Med J Aust 2002; 176: 321-5
29. Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions: so much for guidelines. Pharmacoeconomics 1998; 13: 119-26
30. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001; 19: 855-67
31. Orlewska E, Mierzejewski P. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004; 7: 1-10
32. Nuitjen MJC, Rutten F. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. Pharmacoeconomics 2002; 20: 855-67
33. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained virologic response in genotype 1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9
34. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36 (5 Suppl. 1): S145-51